289 related articles for article (PubMed ID: 15877729)
1. Predicting clinical severity in sickle cell anaemia.
Steinberg MH
Br J Haematol; 2005 May; 129(4):465-81. PubMed ID: 15877729
[TBL] [Abstract][Full Text] [Related]
2. Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment.
Fertrin KY; Costa FF
Expert Rev Hematol; 2010 Aug; 3(4):443-58. PubMed ID: 21083035
[TBL] [Abstract][Full Text] [Related]
3. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH
Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
[TBL] [Abstract][Full Text] [Related]
4. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia.
Nolan VG; Baldwin C; Ma Q; Wyszynski DF; Amirault Y; Farrell JJ; Bisbee A; Embury SH; Farrer LA; Steinberg MH
Br J Haematol; 2005 Jan; 128(2):266-72. PubMed ID: 15638863
[TBL] [Abstract][Full Text] [Related]
5. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
6. Defining stroke risks in sickle cell anemia.
Meschia JF; Pankratz VS
Nat Genet; 2005 Apr; 37(4):340-1. PubMed ID: 15800645
[No Abstract] [Full Text] [Related]
7. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
Rodgers GP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
[TBL] [Abstract][Full Text] [Related]
8. Beta-S gene cluster haplotypes modulate hematologic and hemorheologic expression in sickle cell anemia. Use in predicting clinical severity.
Powars DR; Meiselman HJ; Fisher TC; Hiti A; Johnson C
Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):55-61. PubMed ID: 7508688
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
10. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
11. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
[TBL] [Abstract][Full Text] [Related]
12. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
Segel GB; Simon W; Lichtman MA
Pediatr Blood Cancer; 2011 Jul; 57(1):8-9. PubMed ID: 21480473
[No Abstract] [Full Text] [Related]
13. Genetic polymorphisms associated with priapism in sickle cell disease.
Elliott L; Ashley-Koch AE; De Castro L; Jonassaint J; Price J; Ataga KI; Levesque MC; Brice Weinberg J; Eckman JR; Orringer EP; Vance JM; Telen MJ
Br J Haematol; 2007 May; 137(3):262-7. PubMed ID: 17408468
[TBL] [Abstract][Full Text] [Related]
14. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
15. [Genetic modifiers of homozygous sickle cell disease].
Hartmann K; Kulozik AE
Klin Padiatr; 2006; 218(3):170-3. PubMed ID: 16688674
[TBL] [Abstract][Full Text] [Related]
16. Sickle cell disease: a multigenic perspective of a single gene disorder.
Kutlar A
Hemoglobin; 2007; 31(2):209-24. PubMed ID: 17486504
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
18. The increasing complexity of sickle cell anemia.
Warth JA; Rucknagel DL
Prog Hematol; 1983; 13():25-47. PubMed ID: 6199811
[No Abstract] [Full Text] [Related]
19. Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease.
Wang WC
Exp Biol Med (Maywood); 2016 Apr; 241(7):730-6. PubMed ID: 27026724
[TBL] [Abstract][Full Text] [Related]
20. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F
Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
